Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
2,516,484
-
Share change
-
-292,983
-
Total reported value
-
$1,694,399
-
Put/Call ratio
-
0%
-
Price per share
-
$0.66
-
Number of holders
-
19
-
Value change
-
-$627,914
-
Number of buys
-
10
-
Number of sells
-
8
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q2 2022
As of 30 Jun 2022,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,516,484 shares.
The largest 10 holders included
BVF INC/IL, MORGAN STANLEY, RAYMOND JAMES & ASSOCIATES, Raymond James Financial Services Advisors, Inc., CITADEL ADVISORS LLC, Western Wealth Management, LLC, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, and Cambridge Investment Research Advisors, Inc..
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.